[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100587524":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":27,"centralContacts":28,"locations":34,"responsibleParty":58,"collaborators":27,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":27,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":27,"maxAge":27,"enrollmentInfo":69,"targetDuration":27,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":80,"overallStatus":37,"whyStopped":27,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"University Hospital, Alexandroupolis","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients who will be treated with intravitreal injections of Faricimab","ACTIVE_COMPARATOR","Diabetic patients with either diabetic macular edema (DME) or neovascular age related macular degeneration (nAMD) who will be treated with intravitreal injection of Faricimab.",[13],"Drug: Intravitreal injection of Faricimab or Aflibercept 2 mg",{"label":15,"type":10,"description":16,"interventionNames":17},"Patients who will be treated with intravitreal injections of Aflibercept 2 mg","Diabetic patients with either diabetic macular edema (DME) or neovascular age related macular degeneration (nAMD), or macular edema secondary to retinal vein occlusion who will be treated with intravitreal injection of Aflibercept 2 mg.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Intravitreal injection of Faricimab or Aflibercept 2 mg","Anti-VEGF agents Faricimab (Vabysmo) or Aflibercept 2 mg (Eylea) will be delivered intravitreally",[15,9],[25,26],"Vabysmo","Eylea",null,[29],{"name":30,"role":31,"phone":32,"phoneExt":27,"email":33},"Asli Perente, Dr","CONTACT","+306951577205","asli_perende-90@hotmail.com",[35,53],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"University Hospital of Alexandroupolis","RECRUITING","Alexandroupoli","Evros","68100","Greece","GR",{"type":44,"coordinates":45},"Point",[46,47],25.87644,40.84995,{"lat":47,"lon":46},[50],{"name":51,"role":31,"phone":52,"phoneExt":27,"email":33},"Asli Perente","6951577205",{"facility":36,"status":54,"city":38,"state":27,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":55,"geoPoint":57,"contacts":27},"COMPLETED",{"type":44,"coordinates":56},[46,47],{"lat":47,"lon":46},{"type":59,"investigatorFullName":51,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":27,"oldOrganization":27},"PRINCIPAL_INVESTIGATOR","Consultant Ophthalmologist","100587524","impact-of-intravitreal-faricimab-on-renal-function-in-diabetic-patients-100587524",false,"NCT06929507","Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients","The Impact of Intravitreal Injection of Anti-vascular Endothelial Growth Factor Faricimab on Renal Function in Patients With Diabetes Mellitus","Inclusion Criteria:\n\n* Patients with diabetes\n* Patients with DME or nAMD or macular edema secondary to retinal vein occlusion\n* Patients already receiving nephroprotective drugs\n\nExclusion Criteria:\n\n* Patients with end stage renal disease\n* Pregnancy\n* Patients with other retinal disorders\n* Previous renal transplantation Patients under hemodialysis","ALL",{"count":70,"type":71},60,"ESTIMATED","INTERVENTIONAL",[74],"NA","This study aims to investigate the impact of intravitreal injection of anti-vascular endothelial growth factor (anti VEGF) Faricimab on renal function of diabetic patients. Faricimab is a new anti-VEGF drug which inhibits both VEGF-A and Ang-2 and it is used for the treatment of diabetic macular edema and neovascular age related macular degeneration. It is known that previous anti-VEGF agents has systematic absorption and may cause deterioration in renal function of the patients. However, the effect of Faricimab on kidney function has not been investigated yet. Taking into account that Ang-2 has destructive effect on kidneys, the investigation of the effect of its inhibition in diabetic patients who have already renal function deterioration may provide a valuable information in scientific community.",[77,78,79],"Renal Function Disorder","Diabetic Macular Edema (DME)","Neovascular Age Related Macular Degeneration",[81,82,83,84,85],"renal function","intravitreal injection of anti-VEGF","faricimab","diabetic macular edema","diabetes mellitus","2025-04-19",{"date":88,"type":89},"2025-04-24","ACTUAL",{"date":91,"type":89},"2025-03-10",{"date":93,"type":71},"2027-03-10",{"name":5,"class":6},2]